INTRODUCTION
Renal cell carcinoma (RCC), the most common malignant neoplasm arising from the kidney, accounts for approximately 3% of all human cancers. It is the sixth most common cancer in men and eighth most in women. Every year, an estimated 65,000 people in United States are diagnosed with RCC and approximately 13,500 patients succumb to RCC-related disease (1) . Furthermore, about one-third of RCC patients have already developed metastatic progression at initial diagnosis and up to one half of patients develop distant metastases after primary tumor resection (2) . The 5-year survival rate for patients with metastatic RCC is less than 10% due to acquired resistance of tumors to chemotherapy and radiotherapy. Immunotherapy failed to significantly improve survival as its efficacy was less than 20% (3) . Recent advances in molecular targeting have produced several tyrosine kinase inhibitors (TKI) sunitinib, pazopanib and sorafenib, mTOR inhibitors, and anti-VEGF humanized antibody bevacizumab as the first-line and second-line treatment for systemic therapy of RCC (4) (5) (6) (7) . However, the treatment response is not long-standing and TKI treatment poses risks of serious adverse events (8) .
Various factors contribute to RCC progression and metastasis, Nuclear factor kappa-B (NF-κB) being one of them (9) (10) (11) . Previous studies suggested a definitive role of glycogen synthase kinase-β (GSK-3β) in the regulation of NF-κB activity (12) (13) (14) . GSK-3, a serine/threonine protein kinase, was originally discovered as a protein kinase that phosphorylates and inactivates glycogen synthase (GS), an enzyme involved in glycogen biosynthesis (15, 16) . There are two distinct GSK-3 family members, GSK-3α and GSK-3β (17) , which share more than 98% sequence homology within their kinase domains, only GSK-3α has an extended N-terminal glycine-rich tail (18) isoforms have shared substrates, they exhibit different expression patterns, substrate preferences and cellular functions (12, 19) .
Unlike most protein kinases, GSK-3 is constitutively active in normal conditions and undergoes a rapid and transient inhibition in response to a number of external signals (20) . GSK-3 plays important roles in numerous signaling pathways that regulate a variety of cellular processes (21) (22) (23) (24) (25) . Because of these diverse roles, malfunction of this kinase is also known to be involved in the pathogenesis of human diseases such as diabetes, inflammation, neurological disorders and various neoplastic diseases (18, 26) .
Therefore, GSK-3 is recognized as an attractive target for the development of new drugs.
Several GSK-3 inhibitors have been identified as therapeutic agents in Alzheimer's disease, neurodegenerative disorders and bipolar disorder (27) . Recent studies have shown that GSK-3 inhibitors induce growth suppression and apoptosis in human chronic lymphocytic leukemia (14) , glioma (28) , colon cancer (29) , renal cancer (30) and breast cancer (31) . Additionally, several maleimide-based GSK-3 inhibitors have been shown to elicit excellent anti-proliferative activity in pancreatic (32) and ovarian (33) cancer cells.
In the present study, we analyzed the anti-proliferative effect of both pharmacolgical and genetic inhibition of GSK-3 in two different renal cancer cell lines and explored the underlying mechanism. We have shown that G 0 -G 1 and G 2 -M phase arrest is the most likely cause of this anti-proliferative effect. We further demonstrated that GSK-3 inhibition induces a differentiation phenotype in the renal cancer cells. We have also described that GSK-3 inhibition creates an imbalance in normal energy homeostasis through impaired glucose metabolism in these renal cancer cells which compels them to 
MATERIALS AND METHODS

Reagents.
The antibodies against phospho-GSK-3β, GS, phospho-GS, AMPK-α, phospho-AMPK-α, AMPK-β, phospho-AMPK-β, LC3B and p21 were purchased from Cell Signaling Technology. Antibodies against phospho-p21, Id-1 and cyclin D were purchased from Santa Cruz Biotechnology. Anti-β-actin and Anti-GSK-3β was from BD Biosciences.
Anti-Ksp-Cadherin antibody was purchased from Abcam.
Immunohistochemistry was performed using IHC Select HRP/DAB kit from Millipore. The compound 9-ING-41 was synthesized as previously described (32 protease inhibitor cocktail and with or without phosphatase inhibitor were then prepared.
Supernatant was collected by centrifugation at 13,000 rpm for 10 minutes.
Subsequently, samples were subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinyl difluoride (PVDF) membranes and immunoblotted for the proteins of interest. Antibody-reactive bands were detected by enzyme-linked chemiluminescence (Amersham, Piscataway, NJ).
These experiments were repeated three times.
In vitro apoptosis assay. Cells were seeded in 6 cm dishes and cultured for [18] [19] [20] [21] [22] [23] [24] hours. The next day, cells were treated with either DMSO or increasing concentrations of In vivo anti-tumor activity. Tumors were allowed to grow for 21 days without treatment and mice were then randomized into two groups (six animals per group). Group 1 was treated with PBS containing 50% polyethylene glycol (PEG-400) alone, while group 2 was treated with 9-ING-41 in the above vehicle at doses of 20 mg/kg three times a week intraperitoneally. After 4 weeks of treatment, all tumor-bearing mice were sacrificed by asphyxiation with CO 2 ; tumors were removed, weighed, and prepared for immunochemistry. A part of each tumor was homogenized to obtain lysates which were used for western blot analysis.
Histological Study. Tumors were removed and fixed in neutral buffered 10% formalin at room temperature for 24 hours prior to embedding in paraffin and sectioning. Sections were deparaffinized and then subjected to H&E, Ksp-Cadherin and Ki67 immunochemistry according to the manufacturer's instructions (DAB 150, Millipore).
Stable diaminobenzidine was used as a chromogen substrate, and the sections were counterstained with a hematoxylin solution. Photographs of the entire cross-section were digitized using an Olympus camera (DP70). The Ki67 -positive nuclei were counted in three different sections. To access heterogeneity with regards to proliferation within an individual tumor, sections were taken from three different areas of the tumor and the proliferative index was determined.
Statistical analysis. The independent-samples t-test was used to test the probability of significant differences between groups. Statistical significance was defined as p < 0.05 RESULTS ADME/Tox and PK Profile of 9-ING-41. We carried out an extensive structure−activity relationship analysis, in vitro pharmacology and animal studies on a variety of synthesized GSK-3β analogs, which were inspired by the structure of the natural product staurosporine, a hit identified from a small HTS campaign ( Figure 1A ). From our library of ~100 ATP-competitive GSK-3β inhibitors, the benzofuran-3-yl-(indol-3-yl)maleimide 9-ING-41 has been identified as a potent antiproliferative agent against pancreatic and ovarian cancer cells (32, 33) . This compound was previously shown to attenuate tumor progression in vivo in a xenograft model of SKOV3 ovarian cancer growth (33) .
In order to obtain the kinase selectivity profile, compound 9-ING-41 was tested at a single dose of 10 μM for kinase inhibition in a panel of 320 kinases (Reaction Biology Corp.). The single dose run was performed in duplicates and the average value was measured. Only 35 kinases were found to have less than 50% remaining activity (SI ,   Table S1 ). Representative 11 kinases selected from this group were measured for their IC 50 values ranging from 650 nM to 9410 nM (SI, Table S2 ). The preliminary ADME/Tox properties of 9-ING-41 including CYP inhibition, metabolic stability, plasma protein binding (PPB), and hERG inhibition were also obtained (SI , Table S3 , Stanford
Research Institute International (SRI) and Cerep, Inc.) The inhibitory effect on the in vitro CYP activity in human liver microsomes was screened using a high-throughput multiple CYP assay for CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. In the presence of 10 μM 9-ING-41, none of the CYP isoforms had activity that was less than isoforms. This is especially important for a putative cancer drugs that will likely be used in combination with other agents. The metabolic stability of 9-ING-41 was studied using human liver microsomes, where it was found that 78.9% of the parent compound remained after 60 min of incubation. The IC 50 value for hERG inhibition (patch-clamp) by 9-ING-41 was found to be 21 μM, indicating a low potential for cardiac toxicity. Rangefinding toxicology studies of 9-ING-41 were carried out in male and female SpragueDawley rats. The compound was well tolerated at 500 mg/kg single oral dosage during the toxicity study throughout an 8-day period with no adverse effects observed in body weight, clinical pathology, or gross necropsy findings. Pharmacokinetic analysis of the plasma levels indicated that the volumes of distribution were 10 L/kg suggesting that this compound was well distributed to the tissues and the elimination half-life was 4.85 hr (SI , Table S3 ). Collectively, the compound 9-ING-41 has been demonstrated to possess reasonable PK and ADME/Tox profiles.
GSK-3 inhibition leads to proliferation inhibition in renal cancer cells. We used two renal cancer cell lines, 786-O and A498, which express different levels of GSK-3β and GS for our experiments ( Figure 1B) . When GSK-3β was genetically depleted in these two cell lines, there was a small yet significant inhibition in proliferation ( Figure 1C, 1D and 1E). The effect is slightly more pronounced in 786-O than in A498 which can be explained by a greater abundance of GSK-3β in 786-O cells. When the cells were treated with an ATP-competitive GSK-3 inhibitor, 9-ING-41, a dose-dependent decrease in cell proliferation was observed in both instances ( Figure 1F and 1G) . A 500 nM dose was sufficient for ~40% inhibition in proliferation in both the renal cancer cell lines whereas a 1000 nM dose resulted in almost complete inhibition of proliferation. Taken 
together these findings suggest that GSK-3 plays an important role in cancer cell proliferation. 
9-ING
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on December 10, 2013; DOI: 10.1158/1535-7163.MCT-13-
GSK-3 inhibition affects energy homeostasis and induces autophagy.
We then sought to explore whether increased glucose storage had any effect on normal energy homeostasis in renal cancer cells. Upon GSK-3 inhibition with 9-ING-41 treatment, we found an increase in phosphorylation of both AMPK-α and AMPK-β ( Figure 5A and 5B) suggesting an elevated AMP/ATP ratio which signifies less ATP production and of GSK-3β ( Figure 5C ). This observation led us to hypothesize that in order to maintain the energy needed for cellular processes, cells would enter autophagy. This hypothesis was verified through the observation of increased levels of LC3B as ascertained by both Western blot analysis and immunofluorescence studies ( Figure 5D ). These results indicate that GSK-3 has a regulatory role in maintaining cellular energy homeostasis and dysregulation of this pathway will produce metabolic stress in cells. 
GSK-3 inhibition inhibits
DISCUSSION
It is well documented that GSK-3β is overexpressed in RCC cell lines compared to normal kidney cells and pharmacological inhibition of GSK-3 suppresses proliferation of renal cancer cells (30) . A higher level of phosphorylated Glycogen Synthase, a primary GSK-3 substrate, was also observed in RCC cell lines compared to normal kidney suggesting that GSK-3 is active in RCC. Aberrant nuclear accumulation of GSK-3β was detected in more than 90% human RCC clinical samples and it strongly correlates with phospho-GS expression. This indicates that GSK-3β is active in more than 90% human RCC samples. In contrast, only weak cytoplasmic expression of GSK-3β was found in normal kidney or benign kidney tumors and no phopho-GS was detected in those tissues indicating GSK-3β inactivity. Interestingly, genetic depletion of GSK-3β but not GSK-3α leads to a significant decrease in renal cancer cell proliferation. Previous studies had shown that pharmacological inhibition of GSK-3 resulted in apoptosis induction through decreased expression of NF-κB target genes Bcl-2 and XIAP in pancreatic cancer (13), chronic lymphocytic leukemia (CLL, 14) , and renal cancer (30) . It has also been shown that GSK-3β contributes to the maintenance of active chromatin at Bcl-2 and XIAP promoters, allowing p65 binding and transcriptional activation of Bcl-2 and XIAP in cancer cells (14) . However, GSK-3 regulates numerous cellular processes involving a number of signaling pathways. Accordingly, the NF-κB pathway may not be solely responsible for the anti-proliferative effect exerted by both pharmacological and genetic inhibition of GSK-3.
Here we describe the anti-proliferative effect of a novel ATP-competitive GSK-3 inhibitor, 41 caused cell growth inhibition with IC50<1μM. Genetic depletion of GSK-3β also showed significant inhibition of renal cancer cell proliferation, albeit to a lower extent than 9-ING-41. These observations are in accordance with previous findings (30) and can be explained by the fact that 9-ING-41 cannot discriminate between GSK-3α and GSK-3β and inhibits them equally (SI , Table S1 ).
Since 9-ING-41 inhibited proliferation in the renal cancer cell lines, we decided to analyze its effect on apoptosis induction and cell cycle. We found that 9-ING-41 did not induce apoptosis to a significant extent, but arrests the cells in both G 0 -G 1 and G 2 -M phases. This results in less number of cells in S phase which explained the reduced proliferation as measured by 3 H incorporation. We then checked the expression of two cell cycle regulatory proteins, cyclin D1 and p21, to confirm this. Cyclin D1/Cdk4/6 complex formation is essential for G1 to S phase transition which can be considered as a proliferation index. p21 is a cyclin-dependent kinase inhibitor that directly inhibits the activity of cyclin D1/Cdk4/6 complex thereby inhibiting cell cycle progression. Treatment with 9-ING-41 inhibited cyclin D1 expression as well as phosphorylation and subsequent degradation of p21 in both the renal cancer cell lines tested. A previous study has shown similar results where a GSK-3 inhibitor induced cell death through cyclin D1 depletion in breast cancer cells (31) . Genetic depletion of GSK-3β, on the other hand, increases cyclin D1 expression. So, it may be possible that the cell cycle arrest caused by 9-ING-41 may not be due to GSK-3β inhibition; rather some other pathways may be involved.
However, it should be noted that the genetic depletion of GSK-3β results p21 accumulation as well. So, there is a distinct possibility that the activity of the cyclinD1/Cdk4/6 complex will still be diminished causing cell growth inhibition even if there is an increased cyclin D1 expression. 
In addition to its anti-proliferative effects, 9-ING-41 also imparted a differentiation phenotype to both the renal cancer cell lines tested. A significant increase in Kspcadherin level and simultaneous decrease in Id-1 level were observed upon treatment with 9-ING-41 or genetic depletion of GSK-3β. Simultaneous treatment of 9-ING-41 and GSK-3β siRNA did not show significant additive or synergistic effect on Ksp-cadherin and Id-1 expression which indicates that this differentiation phenotype caused by 9-ING-41 treatment is due to GSK-3 inhibition. Ksp-cadherin is a kidney-specific member of the cadherin family found exclusively in epithelial cells of kidney distal tubules and collecting ducts. Its expression is almost undetectable in RCC samples (38) . Accordingly, the increase in Ksp-cadherin expression upon GSK-3 inhibition indicates transition from a more tumorigenic mesenchymal state to epithelial direction. Id-1, on the other hand, has been shown to be frequently upregulated in RCC and its expression levels are positively associated with both tumor grade and stage (39) . Therefore, the decrease in Id-1 expression upon GSK-3 inhibition signifies decreased tumorigenicity.
Taken together, these data suggest a definitive role of GSK-3 in differentiation and tumorigenicity in renal cancer.
Previous studies reported that GSK-3 plays a role in regulating glucose transport in several cell types and inhibition of GSK-3 resulted in an almost twofold increase in glucose uptake (40) . Here we have shown that upon GSK-3 inhibition by 9-ING-41 treatment or genetic depletion of GSK-3β, the intracellular glucose levels increased in both the renal cancer cell lines. However, GSK-3 inhibition also increases Glycogen Synthase activity promoting the conversion of cellular glucose into glycogen. Hence, we hypothesized that even if glucose uptake is increased upon GSK-3 inhibition, that 
